Project

A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy

Automatically Closed · 2012 until 2013

Type
Clinical Studies
Range
Monocentric project at KSSG
Units
Status
Automatically Closed
Start Date
2012
End Date
2013
Financing
Industry
Study Design
Phase III
Keywords
PF-00299804, Erlotinib, Bronchialkarzinom
Homepage
Partner
-
Additional Information
-
Brief description/objective

Erwartung, dass die Behandlung mit Dacomitinib einem/einer Patienten (-innnen) eine längere Progressions-freie Dauer bietet.